Molecularly targeted agents, such as epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs), have been found to provide substantial clinical benefit in lung cancer patients (Asahina et al, 2006; Sequist et al, 2008; Kwak et al, 2010), and MET is considered a molecular target of potential relevance to lung cancer. Here, EGFR is linked to lung cancer.